FAQ on Scinai Immunotherapeutics Ltd.'s Webinar About PC111 Antibody for Rare Skin Disorders

What is the main topic of the Scinai Immunotherapeutics Ltd. webinar?

The webinar focuses on the treatment potential of Pincell’s novel monoclonal antibody, PC111, for rare skin conditions Pemphigus Vulgaris and SJS/TEN, including its mechanism and development plans.

When is the Scinai Immunotherapeutics Ltd. webinar taking place?

The webinar is scheduled for May 7 at 11:30 a.m. EST.

Who are the panelists in the Scinai Immunotherapeutics Ltd. webinar?

Panelists include executives from Scinai and Pincell, with a live Q&A segment.

What recent developments are related to Scinai Immunotherapeutics Ltd. and PC111?

Scinai’s March agreement to acquire Pincell and a related €12 million grant application under Poland’s FENG program are recent developments related to PC111.

Where can I find more information about Scinai Immunotherapeutics Ltd.?

More information is available on the company’s website at www.Scinai.com and in the company’s newsroom at https://ibn.fm/SCNI.

What are the rare skin conditions targeted by PC111?

PC111 targets Pemphigus Vulgaris and SJS/TEN, which are rare skin conditions with unmet medical needs.

How does PC111 work?

PC111’s mechanism involves targeting soluble Fas ligand, which is part of its approach to treating the mentioned rare skin conditions.

What is the significance of the webinar?

The webinar is significant as it provides insights into the potential of PC111 for treating rare skin conditions, its development plans, and the recent acquisition and grant application by Scinai.

Can I participate in the Q&A segment of the webinar?

Yes, the webinar includes a live Q&A segment where participants can engage with the panelists.

Where can I view the full press release about the webinar?

The full press release can be viewed at https://ibn.fm/BunpC.